GLAXO2,858.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹48,417 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations3,453.73,749.23,821.73,954.9
Other Income122.6145.9145.4145.4
Total Income3,576.33,895.13,967.04,100.3
Expenses
+ Cost of Materials Consumed545.2499.9436.2381.0
+ Purchases of Stock-in-Trade853.1845.1910.51,057.0
+ Changes in Inventories-63.745.94.5-46.8
+ Employee Benefit Expense624.4579.7607.3613.7
+ Finance Costs1.81.32.73.3
+ Depreciation & Amortisation69.766.866.466.8
+ Other Expenses586.1601.3554.2596.4
Total Expenses2,616.52,640.02,581.62,671.5
EBITDA908.71,177.41,309.21,353.5
EBIT839.01,110.61,242.81,286.7
Profit
PBT before Exceptional Items959.81,255.21,385.41,428.9
+ Exceptional Items-143.64.720.620.6
Pretax Income816.21,259.91,406.01,449.5
+ Current Tax237.6326.0360.6368.6
+ Deferred Tax-11.46.39.512.7
Tax Expense226.2332.3370.0381.3
Net Income590.0927.61,036.01,068.2
+ Net Income — Continuing Ops590.0927.61,036.01,068.2
+ Other Comprehensive Income-4.2-2.7-7.5-7.5
Total Comprehensive Income585.8924.91,028.41,060.6
Net Income to Common590.00.0
Per Share
Basic EPS34.8354.5254.5262.01
Diluted EPS34.8354.7654.7663.05
Other Comprehensive Income — detail
+ Other Comprehensive Income-2.7-7.5
+ Items NOT to be Reclassified to P&L-5.6-3.6-10.0
+ Tax on Items NOT to be Reclassified-0.9-2.4
+ Tax on Items NOT to be Reclassified — alt tag-1.4
Comprehensive Income — Owners of Parent-4.20.0
Per Share — as-filed variants
Basic EPS — Continuing Operations34.8354.5254.5262.01
Diluted EPS — Continuing Operations34.8354.7654.7663.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,119.22,358.42,470.62,563.7
Gross Margin %61.3662.9064.6564.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)959.81,255.21,385.41,428.9
− Exceptional Items (reconciliation)-143.64.720.620.6
Net Income Adj (tax-effected)693.8924.11,020.81,053.0
EPS Adj40.9654.3253.7261.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital169.4169.4169.4169.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.